PD-1 regulates the growth of human mastocytosis cells

Allergology International

Volumn 62, Issue 1, 2013, Pages 99-104

  Kataoka, Tatsuki R ^a   Fujimoto, Masakazu ^a   Moriyoshi, Koki ^a   Koyanagi, Itsuko ^a   Ueshima, Chiyuki ^a   Kono, Fumihiko ^b   Tsuruyama, Tatsuaki ^a   Okayama, Yoshimichi ^c   Ra, Chisei ^c   Haga, Hironori ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Inhibitory receptor; KIT; Mast cell; Mastocytosis; PD 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ADULT; ARTICLE; CELL COUNT; CELL GROWTH; CHILD; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MASTOCYTOSIS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WESTERN BLOTTING;

EID: 84875174372     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.12-OA-0450     Document Type: Article

References (26)

1. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24.
2. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
3. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945-54.
4. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal centerassociated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006;30:802-10.
5. Rodríguez-Pinilla SM, Atienza L, Murillo C et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol 2008;32:1787-99.
6. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112:946-56.
7. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006;34:97-115.
8. Nagata H, Worobec AS, Oh CK et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
9. Furitsu T, Tsujimura T, Tono T et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligandindependent activation of c-kit product. J Clin Invest 1993; 92:1736-44.
10. Jensen BM, Akin C, Gilfillan AM. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol 2008; 154:1572-82.
11. Karra L, Berent-Maoz B, Ben-Zimra M, Levi-Schaffer F. Are we ready to downregulate mast cells? Curr Opin Immunol 2009;21:708-14.
12. Hitomi K, Tahara-Hanaoka S, Someya S et al. An immunoglobulin-like receptor, Allergin-1, inhibits immunoglobulin E-mediated immediate hypersensitivity reactions. Nat Immunol 2010;11:601-7.
13. Kataoka TR, Kumanogoh A, Bandara G, Metcalfe DD, Gilfillan AM. CD72 negatively regulates KIT-mediated responses in human mast cells. J Immunol 2010;184:2468-75.
14. Âlvarez-Errico D, Oliver-Vila I, Ainsua-Enrich E et al. CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells. J Immunol 2011;187:5577-86.
15. Kirshenbaum AS, Akin C, Wu Y et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma /leukemia; activation following aggregation of FclRI or FcoRI. Leuk Res 2003;27:677-82.
16. Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345-55.
17. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J ExpMed 2009;206:3015-29.
18. Kataoka TR, Ioka T, Tsukamoto Y, Matsumura M, Ishiguro S, Nishizawa Y. Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas. Int J Surg Pathol 2007;15:277-81.
19. Wang YW, Wang Z, Shi BY. Programmed death 1 mRNA in peripheral blood as biomarker of acute renal allograft rejection. Chin Med J (Engl) 2011;124:674-8.
20. Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal 2005;17:1323-32.
21. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34 (+), c-kit (+), and expresses aminopeptidase N (CD13). Blood 1999; 94:2333-42.
22. Fukao T, Yamada T, Tanabe M et al. Selective loss of gastrointestinal mast cells and impaired immunity in PI3Kdeficient mice. Nat Immunol 2002;3:295-304.
23. Nakae S, Suto H, Iikura M et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 2006;176:2238-48.
24. Benson DM Jr, Bakan CE, Mishra A et al. The PD-1/PDL1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-94.
25. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75.
26. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011;108:7142-7.